Earle A. Chiles Research Institute

Experts in biomedical engineering, immunology and surgical oncology are working collaboratively to improve outcomes for people with head, neck and other cancers.

Providence Cancer Institute to open new clinical study of CAR T-cell therapy to people with clear cell renal cell carcinoma, the most common type of kidney cancer.

First-in-human immune therapy study at Providence Cancer Institute will assess the safety and effectiveness of talquetamab as a potential treatment for cancerous plasma cells known as multiple myeloma

Providence researchers awarded funding from National Cancer Institute to study “Bugs as Drugs.”

Providence Cancer Institute’s Rectal Cancer Program among the first 25 in the nation to earn accreditation from the National Accreditation Program for Rectal Cancer.

Providence Cancer Institute to offer a new phase I/II study of a first-in-class photoimmunotherapy for solid tumors that overexpress the epidermal growth factor receptor protein.

Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute, will join oncology professionals around the world for the 2021 ASCO Annual Virtual Conference.

Providence Cancer Institute to offer phase II clinical trial of neoadjuvant chemotherapy plus immunotherapy for patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A phase II, investigator-initiated clinical trial at Providence Cancer Institute aims to improve survival for patients with triple-negative breast cancer. The trial is available only at Providence.

Learn about a potential immune benefit for infants from lactating mothers who have received a COVID-19 vaccine.

New clinical trial at Providence Cancer Institute combining targeted therapy with checkpoint immunotherapy for patients with metastatic thyroid cancer.

Michael Kelley Endowed Chair for Cancer Research awarded to Providence Cancer Institute radiation oncologist, Dr. Marka Crittenden.

Attendees will have an opportunity to connect with experts in the immunotherapy field at the live virtual event held on Thursday, April 8, 2021.

Three new studies at Providence Cancer Institute will investigate the benefits of adjuvant immunotherapy for patients with completely resected melanoma who are at high risk of recurrence.

Providence Cancer Institute is the only center in the Pacific Northwest to offer a groundbreaking study of adoptive T-cell therapy ADP-A2M4 in combination with the checkpoint inhibitor pembrolizumab.

Advancements in treatment and early detection have improved survival for women diagnosed with breast cancer. For patients with locally advanced or metastatic breast cancer, better therapies are needed

Investigators present latest research in cancer immunotherapy, receive noteworthy awards, at the 35th annual meeting of the Society for Immunotherapy of Cancer.

Providence Cancer Institute is one of the few highly specialized centers offering adoptive cellular therapy for hematologic malignancies. Chimeric antigen receptor (CAR) T-cell therapy is a revolution

Providence Cancer Institute joins oncology professionals around the world for ESMO Virtual Congress 2020, the annual meeting of the European Society for Medical Oncology, held online from September 14